<li>These disease features have been identiÔ¨Åed as placing a person at increased risk for developing ILD; however, the absence of these risk factors does not preclude the development of ILD in patients with these SARDs. Screening for ILD should be performed in shared decision-making with the rheumatologist and patient. As such, screening for ILD should not necessarily be limited only to those with these risk factors. CCP, cyclic citrullinated peptide; ILD, interstitial lung disease; MDA-5, MDA-5